Skip to main content

Neonatal Nursing Education Briefs

H1N1 Influenza


Purpose and Goal: CEARP #1097

  • Describe the clinical manifestations of H1N1 influenza during pregnancy.
  • Identify at least 2 infection control practices that protect newborn infants from H1N1 influenza.

None of the planners, faculty or content specialists has any conflict of interest or will be presenting any off-label product use. This presentation has no commercial support or sponsorship, nor is it co-sponsored. 

Requirements for Successful completion

  • Successfully complete the post-test
  • Complete the evaluation form


  • March 2014 – March 2016

Learning Objectives

  • Describe the clinical manifestations of H1N1 influenza during pregnancy.
  • Describe the prevention and treatment of H1N1 influenza during pregnancy.
  • Identify at least two infection control practices that protect newborn infants from H1N1 influenza.


  • H1N1 influenza originated in Mexico.
  • First detected in the United States in March 2009
  • Peak United States incidence was in October 2009.
  • All 50 states reported infection.
  • Outbreak rapidly spread worldwide.
  • H1N1 remains an annual seasonal risk.
  • Pregnant women are at highest risk.
  • Newly delivered women are also at high risk.

H1N1 Influenza

  • H1N1 influenza is a subtype of influenza A.
    • Most common subtype
  • H1N1 is also known as “swine influenza.”
  • H1N1 represents four strains of influenza
    • Two swine strains
    • One human strain
    • One avian strain
  • Influenza illness in pigs first recognized in 1918
  • Swine virus first isolated from humans in 1974
  • It is unclear how H1N1 was transmitted to humans.
  • H1N1 influenza primarily affects the young.
  • Pregnant women have highest rate of infection.
  • H1N1 influenza uncommon >64 years old

Clinical Presentation

  • Fever
  • Chills
  • Cough
  • Rhinorrhea
  • Sore throat
  • Malaise
  • Headache
  • Shortness of breath
  • Vomiting
  • Diarrhea
  • Myalgia
  • Arthralgia


  • Person-to-person contact
  • Large droplet contact
    • Coughing
    • Sneezing
    • Speaking
  • Nosocomial transmission
    • Patient to patient
    • Patient to healthcare provider
    • Healthcare provider to healthcare provider
  • Viral shedding
  • Begins a day before onset of symptoms
    • Can last for five to seven days or longer
    • Greatest rate of shedding in first two days
  • Incubation period after exposure is one and a half to three days.
  • H1N1 environmental survival
    • 24 to 48 hours on nonporous surfaces
    • 12 hours on porous surfaces
    • Hand washing is critical to avoid exposure.


  • Real-time reverse transcriptase (rRT)-PCR
    • Polymerase chain reaction – uses DNA
    • PCR is most sensitive and specific.
    • Not always immediately available
  • Influenza culture
    • Definitely diagnostic
    • Slower results
  • Rapid antigen test
    • Can distinguish between A and B viruses
    • Cannot distinguish subtypes like H1N1
  • Immunofluorescent antibody testing
    • Can distinguish between A and B viruses
    • Cannot distinguish subtypes like H1N1
  • Serology
    • Useful for influenza surveillance only
    • Can diagnose past influenza illness


  • Vaccination
    • Inactivated influenza vaccine
    • Live attenuated influenza vaccine
    • Vaccine includes both influenza A and B
    • Single vaccine provides protection.
    • Protection occurs within two weeks of vaccine.
    • Center for Disease Control recommendations
      • Healthcare workers
      • Emergency workers
      • Pregnant women
      • Young children after six months
      • Young adults before 24 years
      • Adults 25 to 64 with medical conditions
        • Diabetes
        • Asthma
        • Chronic lung disease
        • Heart disease
  • Antiviral prophylaxis
    • Can be started for any exposure
    • Antiviral medications
      • Oseltamivir (Tamiflu)
      • Zanamivir (Relenza)
  • Personal hygiene
    • Hand hygiene
    • Respiratory hygiene
      • Covering nose and mouth
      • During coughing or sneezing


  • Prompt empiric treatment most beneficial
  • Can be started at any time during illness
  • Decreases severity of illness
  • Antiviral medications
    • Oseltamivir (Tamiflu)
      • Neuraminidase inhibitor
      • 75 mg twice daily for 5 to 10 days 
    •  Zanamivir (Relenza)
      • Neuraminidase inhibitor
      • 10 mg (two inhalations) daily for 5 to 10 days
  • Tamiflu may be preferred due to systemic absorption.

H1N1 Influenza and Pregnancy

  • Pregnant women are at high risk.
    • High risk for severe illness
    • High risk for severe complications
    • High risk for preterm birth
    • High risk for SGA infants
    • High risk for death
  • Newly delivered women also at high risk
    • Up to two weeks post-partum
    • Includes pregnancy losses
  • Physiological changes during pregnancy
    • Decreased immunity
      • Prevents rejection of fetus
      • Increases risk of illness
    • Enlarging uterus
      • Compresses diaphragm
      • Compresses lung tissue
      • Reduces lung volume
      • Predisposes to respiratory infection
  • Live attenuated vaccine is not recommended.
    • Weakened live virus nasal spray
    • Increases chance of illness
    • Safe for newly delivered women
  • Influenza vaccination during pregnancy
    • Protects the pregnant woman
    • Protects the developing fetus
    • Protects the newborn for up to six months
      • Increases maternal IgG antibodies
      • Increases IgA antibodies in breast milk
  • CDC recommends treatment with antiviral medications.
    • All pregnant women with illness
    • All newly delivered women with illness
      • Up to two weeks post-partum
    • Tamiflu is the preferred treatment
      • Enhanced systemic absorption
      • Improved immune response
      • Improved protection of fetus
  • Treatment considered safe at any stage of pregnancy
    • Safe during first trimester
    • Best protection if started at first sign of illness
    • Should be started within 48 hours of illness
  • Increased body temperature from fever
    • Can be harmful to developing fetus
    • Fever should be treated with acetaminophen.
  • Rest and increased fluid intake are important.
  • Increased incidence of severe complications
    • Delay in antiviral treatment >48 hours
    • Severe illness and death
      • Pneumonia
      • Adult respiratory distress syndrome

H1N1 and the Newborn Infant

  • Newborn infants at high risk of illness
    • At risk for severe complications
  • Influenza vaccine not recommended <6 months
  • Healthy newborns born to infected mothers
    • Considered exposed
    • Not considered infected
  • CDC recommendation and guidelines
    • Temporary separation of mother and infant
      • All mothers with suspected influenza
      • All mothers with confirmed influenza
    • Length of separation
      • Until mother treated for 48 hours
      • Until mother afebrile for 24 hours
        • Without use of antipyretics
      • Until mother able to control cough
        • Including respiratory secretions
  • Healthy newborns can be cared for in the nursery.
    • Infants need to be monitored closely. 
  • If separation is not feasible or acceptable
    • Infant should be kept six feet from mother.
    • Healthy family members should care for infant.
  • All feedings should be done by healthy caregivers. 
  • If the mother becomes ill with influenza after discharge
    • Infants should be cared for by healthy family member.
      • If a healthy family member not available
        • Masks should be worn.
        • Hand hygiene is critical.
    • The mother can pump and express breast milk.
    • Breast milk can be safely fed by family member.
    • Antiviral medications are safe to use while breastfeeding.
  • All family members should receive influenza vaccine.
    • Immediate family members
    • Extended family members
    • All household contacts
    • All infant caregivers

Infection Control Practices

  • Control and prevention of influenza outbreak
    • Optimal prevention means prompt identification.
    • Multiple infection control measures are required.
  • CDC guidelines for healthcare settings
    • Promote and administer influenza vaccination.
    • Take steps to minimize exposures.
    • Monitor and manage ill healthcare workers.
    • Adhere to strict standard precautions.
    • Adhere to strict droplet precautions.
    • Manage visitor access and movement.
    • Monitor influenza activity in hospital.
    • Implement environmental infection control.
    • Implement engineering controls.
    • Train and educate healthcare workers.
    • Administer antiviral medications.
      • Healthcare workers
      • Patients and family members
    • Educate patients and family members.


  1. Dunlap, M.M. H1N1 Influenza: Implications for Pregnancy. 2010. Growing Families, 14(2), p. 1-4. 
  2. UpToDate: Influenza and Pregnancy
  3. UpToDate: Clinical Manifestations and Diagnosis of H1N1 Influenza   
  4. UpToDate: Treatment and Prevention of H1N1 Influenza
  5. UpToDate: Infection Control Measures to Prevent Seasonal Influenza in Healthcare Settings

Test and Evaluation

* Required fields

For Referring Providers

Information on referring patients, CIS View, eReferral, PACS Web, accessing medical records, continuing medical education (CME) and more.


The monthly Bulletin newsletter provides updates for healthcare professionals about programs and services at Seattle Children's.

Want to receive the Bulletin via email?